Meg Jardine's Publications

• Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbAinf1cinf, disease duration and treatment intensity: results from the CANVAS Program

  Journal articles

  2021

  Diabetologia

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Journal articles

  2021

  European Heart Journal

• Effects of canagliflozin on hyperkalaemia and serum potassium in people with diabetes and chronic kidney disease: insights from the CREDENCE trial

  Conference Papers

  2021

  EUROPEAN HEART JOURNAL

• Effect of hemodiafiltration on the progression of neuropathy with kidney failure: A randomized controlled trial

  Journal articles

  2021

  Clinical Journal of the American Society of Nephrology

• ANTIPLATELET AGENTS FOR CHRONIC KIDNEY DISEASE: AN UPDATED COCHRANE REVIEW

  Conference Papers

  2021

  NEPHROLOGY

• MEDIATORS OF THE EMPAGLIFLOZIN TREATMENT EFFECT ON KIDNEY OUTCOMES IN THE EMPA-REG OUTCOME TRIAL

  Conference Papers

  2021

  NEPHROLOGY

• Effect of a medium cut-off dialyzer on protein-bound uremic toxins and mineral metabolism markers in patients on hemodialysis

  Journal articles

  2021

  Hemodialysis International

• Canagliflozin, serum magnesium and cardiovascular outcomesAnalysis from the CANVAS Program

  Journal articles

  2021

  Endocrinology, Diabetes and Metabolism

• The effects of canagliflozin on heart failure and cardiovascular death by baseline participant characteristics: Analysis of the CREDENCE trial

  Conference Abstracts

  2021

  Diabetes, Obesity and Metabolism

• Kidney and Cardiovascular Effects of Canagliflozin According to Age and Sex in the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• The Impact of Canagliflozin on the Risk of Neuropathy Events: Results from the CREDENCE Trial

  Journal articles

  2021

  DIABETES

• Canagliflozin Improves Cardiovascular and Renal Outcomes across Broad Geographic Regions: Results from CREDENCE

  Journal articles

  2021

  DIABETES

• Variability in estimated glomerular filtration rate and the risk of major clinical outcomes in diabetes: Post hoc analysis from the ADVANCE trial

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• Blood Pressure Effects of Canagliflozin and Clinical Outcomes in Type 2 Diabetes and Chronic Kidney Disease: Insights From the CREDENCE Trial

  Journal articles

  2021

  Circulation

• Effect of SGLT2 inhibitors on stroke and atrial fibrillation in diabetic kidney disease: Results from the CREDENCE trial and meta-analysis

  Journal articles

  2021

  Stroke

• In response

  Journal articles

  2021

  Annals of Internal Medicine

• Relationship between measured and prescribed dialysate sodium in haemodialysis: A systematic review and meta-Analysis

  Journal articles

  2021

  Nephrology Dialysis Transplantation

• Quality of Life in Caregivers of Patients Randomized to Standard- Versus Extended-Hours Hemodialysis

  Journal articles

  2021

  Kidney International Reports

• Insights from CREDENCE trial indicate an acute drop in estimated glomerular filtration rate during treatment with canagliflozin with implications for clinical practice

  Journal articles

  2021

  Kidney International

• Cardiovascular and renal outcomes with canagliflozin according to baseline diuretic use: a post hoc analysis from the CANVAS Program

  Journal articles

  2021

  ESC Heart Failure

• Innovating and invigorating the clinical trial infrastructure for glomerular diseases

  Journal articles

  2021

  Kidney International

• The International Society of Nephrology Advancing Clinical Trials (ISN-ACT) Network: current activities and future goals

  Journal articles

  2021

  Kidney International

• Effects of canagliflozin on cardiovascular, renal, and safety outcomes in participants with type 2 diabetes and chronic kidney disease according to history of heart failure: Results from the CREDENCE trial

  Journal articles

  2021

  American Heart Journal

• The effects of dipeptidyl peptidase-4 inhibitors on kidney outcomes

  Journal articles

  2021

  Diabetes, Obesity and Metabolism

• SGLT2 inhibitors may offer benefit beyond diabetes

  Journal articles

  2021

  Nature Reviews Nephrology

• Comparison of Circulating Biomarkers in Predicting Diabetic Kidney Disease Progression With Autoantibodies to Erythropoietin Receptor

  Journal articles

  2021

  Kidney International Reports